

Migliorare l'outcome nell'ipertensione arteriosa polmonare: le nuove possibilità terapeutiche

Sergio Harari

MILANO • 13 // 14 dicembre 2018 PALAZZO DELLE STELLINE

Division of Pulmonary Disease, Reference Centre for Rare pulmonary diseases IRCCS MultiMedica San Giuseppe Hospital Milan Italy





- Roche: investigator in trials, lectures, AB
- Actelion : investigator in trials, lectures, AB, grant for research
- Boehringer Ing. : investigator in trials, lectures, AB, grant for research

Task Force #6: Risk Stratification and Medical Therapy of Pulmonary Arterial Hypertension






Nazzareno Galié (Bologna, Italy) Vallerie V. McLaughlin (Ann Arbor MI, USA)

Richard N. Channick (Boston MA, USA) Robert P. Frantz (Rochester MN, USA) Ekkehard Grünig (Heidelberg, Germany) Zhi Cheng Jing (Shanghai, China) Olga Moiseeva (Saint Petersburg, Russia) Ioana R. Preston (Boston MA, USA) Zeenat Safdar (Houston TX, USA) Yuchi Tamura (Tokyo, Japan) Tomas Pulido (Mexico City, Mexico)



Risk assessment is fundamental for the determination of an optimal treatment strategy





^a Some WHO-FC III patients may be considered high-risk;

^b Initial combination with ambrisentan plus tadalafil has proven to be superior to initial monotherapy with ambrisentan or tadalafil in delaying clinical failure;

^c Intravenous epoprostenol should be prioritized as it has reduced the 3 month rate for mortality in high-risk PAH patients also as monotherapy.

Galiè N, *et al. Eur Respir J* 2015; 46:903-75;
 Galiè N, *et al. Eur Heart J* 2016; 37:67-119.

Risk Prediction Tools in PAH



Risk equations or models currently available to predict outcomes in PAH

- 1. NIH registry equation¹
- 2. French network equation^{2,3}
- 3. PH Connection (PHC) equation^{4,5}
- 4. Scottish composite score⁶
- 5. **REVEAL** equation⁷ and risk score⁸
- 6. ESC/ERS risk stratification table⁹

1. D'Alonzo. Ann Intern Med 1991. 2. Humbert. Circulation 2010. 3. Humbert. Eur Respir J 2010. 4. Thenappan. Eur Respir J 2010. 5. Thenappan. Chest 2012. 6. Lee. Eur Respir J 2012. 7. Benza. Circulation 2010. 8. Benza. Chest 2012. 9. Galiè N, Eur Heart J 2016 & Eur Respir J 2015.

Recommendations for evaluation of PAH severity and response to therapy



	Recommendations for evaluation of PAH severity and response to therapy	Class	Level
Risk Stratification	It is recommended to evaluate the severity of PAH patients with a panel of data derived from clinical assessment, exercise tests, biochemical markers and echocardiographic and hemodynamic evaluations	I	С
Stratification	It is recommended to perform regular follow-up assessments every 3 - 6 months in stable patients	1	С
Treatment	Achievement/maintenance of a low-risk profile is recommended as an adequate treatment response for patients with PAH	I.	С
goal	Achievement/maintenance of an intermediate-risk profile should be considered an inadequate treatment response for most patients with PAH	lla	С

Galiè N, *et al. Eur Respir J* 2015; 46:903-75;
 Galiè N, *et al. Eur Heart J* 2016; 37:67-119.

Summary of four registries assessing risk scores



	REVEAL ¹	SPAHR ²	COMPERA ³	FPHN ⁴
Required variables, <i>n</i>	12 - 14	8	8	4
Patients at baseline, <i>n</i>	2716	530	1588	1017
Patients at follow up, <i>n</i>	2529	383	1094	1017
Associated-PAH included	Yes	Yes	Yes	Νο
Definition of low-risk	≤ 6 REVEAL score	<1.5 Average score	< 1.5 Average score	3-4 of 4 low-risk criteria
1-year mortality by risk group (low/intermediate/high), %	≤2.6 / 7.0 / ≥10.7	1.0 / 7.0 / 26.0	2.8 / 9.9 / 21.2	1.0 / NA / 13.0-30.0

1. Benza RL, et al. J Heart Lung Transplant. 2015;34:356-61.

2. Kylhammar D, et al. Eur Heart J 2017; ehx257.

3. Hoeper MM, et al. Eur Respir J 2017; 50:1700740.


4. Boucly A, et al. Eur Respir J 2017; 50:1700889.

The REVEAL score



- Score from 0 (low risk) to 22 (high risk)
- Estimated survival at 1 year
- Incident/prevalent cases

Survival according to risk score at enrollment



Benza RL, et al. Circulation 2010. Benza RL, et al. Chest 2012.

2015 ESC/ERS Guidelines – Risk stratification in PAH



Determinants of		Estimated 1-year mortality		
prognosis	Low risk < 5%	Intermediate risk 5-10%	High risk > 10%	
Clinical signs of right heart failure	Absent	Absent	Present	
Progression of symptoms	No	Slow	Rapid	
Syncope	No	Occasional syncope	Repeated syncope	
FC	I, II	Ш	IV	
6MWD	> 440 m	165 - 440 m	< 165 m	
CPET	Peak VO ₂ > 15 ml/min/kg (> 65% pred.) VE/VCO ₂ slope < 36	Peak VO ₂ 11 - 15 ml/min/kg (35-65% pred.) VE/VCO ₂ slope 36 - 44.9	Peak VO ₂ < 11ml/min/kg (< 35% pred.) VE/VCO ₂ slope ≥ 45	
NT-proBNP plasma levels	BNP < 50 ng/l NT-proBNP < 300 ng/l	BNP 50–300 ng/l NT-proBNP 300–1400 ng/l	BNP > 300 ng/l NT-proBNP > 1400 ng/l	
Imaging (echo, CMR)	RA area < 18 cm ² No pericardial effusion	RA area 18–26 cm ² No or minimal pericardial effusion	RA area > 26 cm ² Pericardial effusion	
Hemodynamics	RAP < 8 mmHg Cl ≥ 2.5 l/min/m ² SvO ₂ > 65%	RAP 8–14 mmHg CI 2.0–2.4 I/min/m ² SvO ₂ 60–65%	RAP > 14 mmHg CI < 2.0 l/min/m ² SvO ₂ < 60%	


Clinical Evaluation

Exercise Capacity

Right Ventricular Function

2015 ESC/ERS Guidelines – Risk stratification in PAH





Slide courtesy of Nazzareno Galiè

Validation of ESC/ERS risk stratification for PAH





Example Sector Example Address (2017) 0.1.7 CLINICAL RESEARCH Pulmonary circulation A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension David Kylhammar ^{1*} , Barbro Kjellström ² , Clara Hjalmarsson ³ , Kjell Jansson ⁴ , Magnus Nisell ⁵ , Stefan Söderberg ⁶ , Gerhard Wikström ⁷ , and Göran Rådegran ¹ , on behalf of SveFPH and SPAHR	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Marius M. Hoeper ^{1,2} , Tilmann Kramer ^{3,4} , Zixuan Pan ⁵ , Christina A. Eichstaedt ⁵ , Jens Spiesshoefer ⁶ , Nicola Benjamin ⁵ , Karen M. Olsson ^{1,2} , Katrin Meyer ¹ , Carmine Dario Vizza ^{©7} , Anton Vonk-Noordegraaf ⁸ , Oliver Distler ⁹ , Christian Opitz ¹⁰ , J. Simon R. Gibbs ¹¹ , Marion Delcroix ¹² , H. Ardeschir Ghofrani ¹³ , Doerte Huscher ¹⁴ , David Pittrow ¹⁵ , Stephan Rosenkranz ^{3,4} and Ekkehard Grünig ^{2,5}	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Athénaïs Boucly ^{1,2,3} , Jason Weatherald ^{2,3,4} , Laurent Savale ^{1,2,3} , Xavier Jaïs ^{1,2,3} , Vincent Cottin ⁵ , Grégoire Prevot ⁶ , François Picard ⁷ , Pascal de Groote ⁸ , Mitja Jevnikar ^{1,2,3} , Emmanuel Bergot ⁹ , Ari Chaouat ^{10,11} , Céline Chabanne ¹² , Arnaud Bourdin ¹³ , Florence Parent ^{1,2,3} , David Montani ^{1,2,3} , Gérald Simonneau ^{1,2,3} , Marc Humbert ^{1,2,3} and Olivier Sitbon ^{1,2,3}
Kylhammar (8 variables)	Hoeper (6 variables)	Boucly (4 or 3 variables)
<i>n</i> = 530 PAH (2008-2016)	<i>n</i> = 1588 PAH (2009-2016)	<i>n</i> = 1017 IPAH (2006-2016)
WHO 6MWD BNP RA area Pericardial effusion RAP CI SvO ₂	WHO 6MWD BNP RAP CI SvO ₂	WHO 6MWD RAP CI WHO 6MWD BNP
Sum of grades (1 low-3 high) /number available variables	Sum of grades (1 low-3 high) /number available variables	Number of low risk variables

Kylhammar D, et al. Eur Heart J 2017; ehx257; Hoeper MM, et al. Eur Respir J 2017; 50:1700740; Boucly A, et al. Eur Respir J 2017; 50:1700889.


Validation of ESC/ERS risk stratification in large registries








SPAHR: change in risk status




Kylhammar D, *et al. Eur Heart J* 2017; Epub ahead of print;
 Hoeper MM, *et al. Eur Respir J* 2017; 50:1700740.

Achievement of multiple low risk criteria is associated with improved long-term outcomes






Follow-up



Number of non-invasive low-risk criteria at follow-up is also associated with prognosis






Non-invasive low-risk criteria: NYHA FC I-II 6MWD >440 m BNP <50 ng/L or NT-proBNP <300 ng/L

Patients with all 3 non-invasive low-risk criteria had a 2-, 3- and 5-year survival of 100%, 99% and 97%, respectively

Non-invasive measurements were WHO/NYHA FC, 6MWD and either BNP or NT-proBNP

- 579 idiopathic PAH
- 1st f-up (median 4.6 months)
- 3 non invasive criteria:
 - NYHA FC I-II
 - 6MWD > 440m
 - BNP < 50 ng/L or
 NT-proBNP < 300 ng/mL



Duration since follow-up risk assessment years

Hoeper M, et al. Eur Respir J 2018; 51: 1702606.

Validation of the french methodology in COMPERA



Limitations of Risk Assessment



- Data derived from retrospective and prospective observational registries
- Data collection was not standardized in all published registries
- Significant missing data and patients lost to follow-up (SPAHR & COMPERA)
- Other important prognostic features, e.g. imaging, Echo, and CPET, were not collected systematically
- Intermediate risk patients is the largest group

Proposal of a simplified risk assessment in pulmonary arterial hypertension



Risk Criteria	Determinants of Prognosis ^a (estimated 1-year mortality)	Low Risk Variables (<5%)	Intermediate Risk Variables (5-10%)	High Risk Variables (>10%)
Α.	WHO functional class	I, II		IV
В.	6MWD	> 440 m	165–440 m	< 165 m
C. D.	NT-proBNP/BNP plasma levels or RAP CI or SvO2	BNP < 50 ng/l NT-proBNP < 300 ng/l or RAP < 8 mmHg Cl ≥ 2.5 l/min/m ² or SvO ₂ > 65%	BNP 50–300 ng/l NT-proBNP 300–1400 ng/l or RAP 8–14 mmHg Cl 2.0–2.4 l/min/m ² or SvO ₂ 60–65%	BNP > 300 ng/l NT-proBNP > 1400 ng/l or RAP > 14 mmHg Cl < 2.0 l/min/m ² or SvO ₂ < 60%
Individual Risk Category Definition		Low Risk Definition	Intermediate Risk Definition	High Risk Definition
		At least 3 low risk criteria and no high risk criteria	Definitions of low or high risk not fulfilled	At least 2 high risk criteria including Cl or SvO2



Slide courtesy of Nazzareno Galiè


WSPH 2018, in revision.

Risk stratification at baseline and follow-up



BASELINE EVALUATION

TREATMENT RESPONSE



----- Low ------ Intermediate ------ High

Slide courtesy of Nazzareno Galiè

Dardi F, et al.. ESC 2018.

Recommendations for evaluation of PAH severity and response to therapy




th WSPH	Recommendations for evaluation of PAH severity and response to therapy	Class	Level
Risk Stratification	It is recommended to evaluate the severity of PAH patients with a panel of data derived from clinical assessment, exercise tests, biochemical markers and echocardiographic and hemodynamic evaluations	I	c > B
Stratification	It is recommended to perform regular follow-up assessments every 3 - 6 months in stable patients	I.	c > B
Treatment	Achievement/maintenance of a low-risk profile is recommended as an adequate treatment response for patients with PAH	I.	c > B
goal	Achievement/maintenance of an intermediate-risk profile should be considered an inadequate treatment response for most patients with PAH	lla	c > B

Galiè N, *et al. Eur Respir J* 2015; 46:903-75;
 Galiè N, *et al. Eur Heart J* 2016; 37:67-119.

Current PAH-targeted medications: Targeting 3 major pathways of endothelial dysfunction






Circulation. 2014;130:2189-208.

*Only approved in the US; **Only approved in Japan and South Korea

Time-course of completed and published RCTs in PAH (41): Therapy Strategy



9061: PAH patients in RCTs




RCTs on monotherapy vs placebo or vs monotherapy (21) RCTs on monotherapy and/or sequential combination vs placebo (18) RCTs on initial combination vs monotherapy (2)

Meta-analyses comparison on all-cause mortality




MONOTHERAPY

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses




25 RCTs, 3839 patients Events = 86 Average Mortality = 2.5% Average Exposure Period = 14.2 weeks

SEQUENTIAL COMBINATION




Meta-analyses comparison on all-cause mortality





Combination therapy: New endpoints/ New strategies





Drug tested	Study	Background	N	Duration (weeks)	Primary endpoint
Bosentan	COMPASS-21	Sildenafil	334	92	Time to first occurrence of death or morbidity event (NEG)
Macitentan	SERAPHIN ²	None (36%), PDE5i (61%) or oral/inhaled prostanoids	742	≈ 100	Time to first occurrence of death or morbidity event (POS)
Selexipag	GRIPHON³	None (21%),ERA (13%), PDE5i (32%) or both (34%)	1156	≈ 70	Time to first occurrence of death or morbidity event (POS)
Ambrisentan + tadalafil	AMBITION ⁴	None (incident cases)	500	≈ 74	Time to first occurrence of clinical failure event (POS)


1. McLaughlin VV, et al. Eur Respir J 2015. 2. Pulido T, et al. N Engl J Med 2013. 3. Sitbon O, et al. N Engl J Med 2015. 4. Galié N, et al. N Engl J Med 2015.

SERAPHIN & GRIPHON: macitentan and selexipag reduced the risk of the primary outcome composite of death or morbidity due to PAH



SERAPHIN¹


GRIPHON²





1. Pulido T, *et al. N Engl J Med* 2013; 369:809-18. 2. Sitbon O, et al. *N Engl J Med* 2015;373:2522-33.

SERAPHIN & GRIPHON Landmark analysis: Morbidity events were prognostic for mortality









В	H	Hazard Rat	io and 95% CI			Prior Morbio	lity Event	No Prior Mo	rbidity Event
-	0.1	0.4	2 4 6 10	HR	95% CI	Patients	Events	Patients	Events
Month 3			⊢∎⊣	4.48	2.98-6.73	62	30	1065	160
Month 6			⊢∎⊣	4.10	2.86-5.87	106	42	983	120
Month 12			⊢∎⊣	3.52	2.34-5.31	147	37	817	72
	0.1 Decrea	0.4 sed Risk	2 4 6 10 Increased Risk						

McLaughlin VV, et al. J Am Coll Cardiol 2018;71:752-63

Initial combination therapy: What is the evidence?




Measure/			Class ^a	-Level	Ь		
treatment		O-FC		O-FC		O-FC V	
Ambrisentan + tadalafil ^d	Т	В	Т	В	Шь	с	AMBITION: Galiè N, et al. N Engl J Med 2015;273:8
Other ERA + PDE-5i	lla	с	lla	с	Шь	с	Sitbon O, <i>et al. Eur Respir J</i> 2016;47:1727-36.
Bosentan + sildenafil + i.v. epoprostenol	-	-	lla	с	lla	с	Sitbon O, <i>et al. Eur Respir J.</i> 2014;43:1691–7.
Bosentan + i.v. epoprostenol	-	-	lla	с	lla	с	BREATHE-2: Humbert M, <i>et al. Eur Respir J.</i> 2004;24:3 Kemp K, <i>et al. J Heart Lung Transplant</i> 2012;31:150–8.
Other ERA or PDE-5i + s.c. treprostinil			Шь	с	Шь	с	
Other ERA or PDE-5i + other i.v. prostacyclin analogues			ΠΡ	с	ШЬ	с	TRITON study (macitentan, tadalafil, ± selexipag) ongoing Galiè N, Humbert M, <i>et al. Eur Respir J</i> 2015;46:903


AMBITION: Initial combo of ambrisentan AND tadalafil is superior to monotherapy with ambrisentan OR tadalafil



- N=500 treatment-naïve patients with PAH (31% FC II)
- **Primary endpoint**: Time to the first occurrence of a composite endpoint of death, hospitalization for PAH worsening, disease progression, or unsatisfactory long-term clinical response



Hospitalisation for PAH worsening was the main component of the primary endpoint



Galiè N, et al. N Engl J Med 2015;273:834:44.

Initial dual oral combination in PAH: A matter of drugs or a question of strategy?



	AMBITION-BONSAI* Ambrisentan + tadalafil (n=19) ¹	Joint–INTENTION [#] Bosentan + sildenafil (n=23) ²	French Network Cohort ERA + PDE5i (n=97) ³	OPTIMA Macitentan + tadalafil (n=16) ⁴
Δ RAP (%)	-17	- 36	-29	-10
Δ mPAP (%)	-33	- 21	-16 (-10 mmHg)	-22 (-10 mmHg)
∆ CI (%)	+56	+63	+46 (+1 L/min/m ²)	+45 (+1 L/min/m ²)
Δ PVR (%)	-61	-60	-45 (from 12.7 WU)	-54 (from 10 WU)
Δ 6MWD (%)	+25	+ 42	+22 (+71 m)	+8 (+27 m)

*BONSAI: BOlogNa Sub-study on hAemodynamics

[#]Joint Bologna and Calgary study on INiTial bosENTan plus slldenafil in pulmonary arterial hypertension.

1. Bachetti C et al. Am J Respir Crit Care Med 2015;191:A479.

2. Palazzini M et al. Am J Respir Crit Care Med 2016;193:A6317.


3. Sitbon O et al. Eur Respir J 2016;47:1727-36.

4. Sitbon O et al. Presented as poster at ATS conference 2017.


Initial triple combination therapy in severe PAH: Treatment benefit on FC and hemodynamics



Prospective, observational analysis of idiopathic or heritable PAH patients (n = 19) treated with triple initial combination therapy (epoprostenol, bosentan and sildenafil)



	Baseline	4-month	Last visit (32 ± 19 months)
RAP (mmHg)	11.9 ± 5.2	4.9 ± 4.9*	5.2 ± 3.5*
mPAP (mmHg)	65.8 ± 13.7	45.7 ± 14.0*	44.4 ± 13.4*
CI (I/min/m ²)	1.66 ± 0.35	3.49 ± 0.69*	3.64 ± 0.65*
PVR (d.s.cm ⁻⁵)	1718 ± 627	564 ± 260*	492 ± 209*
SvO ₂ (%)	51.0 ± 8.5	69.7 ± 5.2*	72.2 ± 4.0*






Residual role for monotherapy



- I/H/D PAH patients **responders to acute vasoreactivity tests** and with near-normalization of symptoms, exercise capacity, PAP and PVR on highest tolerated doses of CCBs
- Long-term treated historical PAH patients with monotherapy (> 5-10 years) stable with low risk profile
- **PAH patients > 75 yo with multiple risk factors for HFpEF** (high blood pressure, diabetes mellitus, coronary artery disease, atrial fibrillation, obesity)
- PAH patients with suspicion or high probability of **PVOD/PCH**
- Patients with PAH associated with HIV or portal hypertension or uncorrected CHD as they were not included in RCTs of initial combination therapy
- PAH patients with **very mild disease** (e.g. FC I, PVR < 4 WU, mPAP < 30 mmHg, normal RV)
- Combination therapy unavailable or contraindicated (e.g. severe liver disease)



Conclusions



- Multiparametric evaluation is essential to evaluate prognosis and optimal therapeutic strategy
- Low risk cathegory need a clear definition and could be a tstatus to attend and mantain
- Intensive follow up is necessary for all pts to adapte and ev. Increase (combination) therapy
- Double therapy is now the most appropriate therapy for the vast majority of intermediate risk pts
- For more severe pts a parenteral PC associated to 2 oral drugs is recommended